In the pan-cancer cohort (TCGA-PANCAN*) and the in-house ovarian cancer cohort, the level of fdeam was not significantly different between monoallelic BRCA1/2-mutated tumors and tumor without alteration in the HR pathway. The gene discussed is BRCA1; the disease is cancer.